HomeSGX-LISTED COMPANIESSheffield Green's Strong FY2025: Revenue, Profit, and Global Expansion

Sheffield Green’s Strong FY2025: Revenue, Profit, and Global Expansion

Published on

spot_img

Sheffield Green Ltd. (SGL) experienced a year of strategic expansion and disciplined execution in FY2025, driven by new client acquisitions and broadened operations across key global markets. The Group is strengthening its presence in the fastest-growing offshore wind markets and remains confident in capturing emerging employment and talent opportunities in the renewable energy value chain.

• Explore how strategic growth initiatives propelled Sheffield Green’s performance

• Uncover the new markets and expanded services driving the company’s global footprint

• Learn about their key investments in human resources and training that align with industry trends

LISTEN TO THE PODCAST BELOW:

Latest articles

Top Glove Q3 FY2026 Earnings Rise Despite Fluctuating Material Costs

Resilient Growth and Strategic Agility Top Glove Corporation has reported a remarkable 138% year-on-year surge...

AstraZeneca invests US$20M to curb Malaysia chronic disease burden

AstraZeneca is scaling up early screening and clinical research efforts in Malaysia as the...

AstraZeneca expands diagnostics and AI to tackle late-stage cancer deaths

AstraZeneca is sharpening its long-term AstraZeneca cancer strategy with a combination of heavy research...

AstraZeneca deploys AI to cut drug timelines by 30% and boost survival

AstraZeneca is stepping up its investment in AI drug discovery to shorten treatment timelines...

More like this

Top Glove Q3 FY2026 Earnings Rise Despite Fluctuating Material Costs

Resilient Growth and Strategic Agility Top Glove Corporation has reported a remarkable 138% year-on-year surge...

AstraZeneca invests US$20M to curb Malaysia chronic disease burden

AstraZeneca is scaling up early screening and clinical research efforts in Malaysia as the...

AstraZeneca expands diagnostics and AI to tackle late-stage cancer deaths

AstraZeneca is sharpening its long-term AstraZeneca cancer strategy with a combination of heavy research...